Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Gaetan Catala"'
Autor:
Jean-Marie Michot, Wolfgang Jacob, Francesca Michielin, Martin Weisser, Dmitriy Zamarin, Jean-Pascal Machiels, Anna-Maria Jegg, Dominik Rüttinger, Konstanty Korski, Jean-Pierre Delord, Carlos Gomez-Roca, Tara Mitchell, Gaetan Catala, Lauriane Eberst, Michael A Cannarile, Carl Watson, Galina Babitzki, Irina Klaman, Priscila Teixeira, Sabine Hoves, Carola Ries, Georgina Meneses-Lorente, Randolph Christen, Philippe Cassier
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background This phase Ib study evaluated the safety, clinical activity, pharmacokinetics, and pharmacodynamics (PD) of emactuzumab (anti-colony stimulating factor 1 receptor monoclonal antibody (mAb)) in combination with selicrelumab (agonistic clust
Externí odkaz:
https://doaj.org/article/f591763d90694aa3ace112662e809f8f
Autor:
Anne Sibille, Frederique Bustin, Luciano Carestia, Gaetan Catala, Christophe Compère, Kristof Cuppens, Benoit Colinet, Stephanie Coulon, Nele De Brucker, Lore Decoster, Lynn Decoster, Ingel Demedts, Sofie Derijcke, Koen Deschepper, Danny Galdermans, Annelies Janssens, Sebahat Ocak, Christel Oyen, Karin Pat, Thierry Pieters, Vincent Pruniau, Veerle Surmont, Saar Vandekeere, Johan Vansteenkiste
Publikováno v:
Acta oncologica
Acta oncologica (Stockholm, Sweden), Vol. 61, no. 6, p. 773-776 (2022)
Acta oncologica (Stockholm, Sweden), Vol. 61, no. 6, p. 773-776 (2022)
Medical writing and editorial assistance were provided by Tim Ibbotson, PhD, of ApotheCom (Yardley, PA, USA) and funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Statistical analysis was done by Herbert Thi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eaa79d19a81a12ecdb48210dc208165b
Autor:
Anke Van den Broeck, Luc Somers, Guy Jerusalem, Didier Verhoeven, Ahmad Awada, François Duhoux, Jeroen Mebis, Jean-Pascal Machiels, Alain Bols, Gaetan Catala
Publikováno v:
Acta clinica Belgica, Vol. 75, no. 2, p. 128-135 (2020)
Chemotherapy plays an important role in the treatment of early breast cancer (EBC). Granulocyte-colony stimulating factors (G-CSF) can reduce the risk of febrile neutropenia as primary prophylaxis (PP) or secondary prophylaxis (SP). The BRONS study i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82717229805a8ec5fd39fc55e306e4b8
https://doi.org/10.1080/17843286.2018.1563735
https://doi.org/10.1080/17843286.2018.1563735
Autor:
Carola Ries, Priscila Camillo Teixeira, Dominik Rüttinger, Carlos Gomez-Roca, Wolfgang Jacob, Francesca Michielin, Martin Weisser, Georgina Meneses-Lorente, Jean-Marie Michot, Lauriane Eberst, Anna-Maria Jegg, Irina Klaman, Jean-Pierre Delord, Sabine Hoves, Galina Babitzki, Michael A. Cannarile, Philippe A. Cassier, Jean-Pascal Machiels, Konstanty Korski, Carl Watson, Tara C. Mitchell, Randolph Christen, Gaetan Catala, Dmitriy Zamarin
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for ImmunoTherapy of Cancer, Vol. 8, no. 2, p. e001153 [1-12] (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for ImmunoTherapy of Cancer, Vol. 8, no. 2, p. e001153 [1-12] (2020)
BackgroundThis phase Ib study evaluated the safety, clinical activity, pharmacokinetics, and pharmacodynamics (PD) of emactuzumab (anti-colony stimulating factor 1 receptor monoclonal antibody (mAb)) in combination with selicrelumab (agonistic cluste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a84d90eef6ef770b34576e40e3415f6
https://doi.org/10.1136/jitc-2020-001153
https://doi.org/10.1136/jitc-2020-001153
Autor:
Gaetan Catala, David E Gilham, Ahmad Awada, Philippe Aftimos, Caroline Lonez, Frederic Lehmann, Jean-Pascal Machiels, Eric Van Den Neste, Bikash Verma, Alain Hendlisz, Jason Brayer, David A Sallman, Fanny Piette, Marco L. Davila, Tessa Kerre, Kunle Odunsi
Publikováno v:
BMJ Open, Vol. 7, no.11, p. e017075 (2017)
BMJ OPEN
BMJ Open
BMJ open, 7 (11
BMJ open, Vol. 7, no.11, p. e017075 (2017)
BMJ OPEN
BMJ Open
BMJ open, 7 (11
BMJ open, Vol. 7, no.11, p. e017075 (2017)
Introduction NKR-2 are autologous T cells genetically modified to express a chimeric antigen receptor (CAR) comprising a fusion of the natural killer group 2D (NKG2D) receptor with the CD3 signalling domain, which associates with the adaptor molecule
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37c4feb1ca09fcdee3446f37adb21ae0
https://hdl.handle.net/2078.1/219417
https://hdl.handle.net/2078.1/219417
Autor:
Kunle Odunsi, David E Gilham, Philippe Lewalle, U Santanam, Jason Brayer, Gaetan Catala, Solmaz Sahebjam, Philippe Aftimos, J-P. Machiels, David A Sallman, Frederic Lehmann, Ahmad Awada, Nathalie Meuleman, Tessa Kerre, Eunice S. Wang, E Vandenneste, Sylvie Rottey, Bikash Verma, Caroline Lonez
Publikováno v:
Annals of Oncology. 28:v426
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3e9d09b115efcc4a428d366ef1719ba
https://doi.org/10.1093/annonc/mdx376.070
https://doi.org/10.1093/annonc/mdx376.070
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.